Estados Unidos · Plataformas y datos · TradingView
Johnson & Johnson looking to buy Ollin Biosciences for up to $3.4 billion, FT says

Resumen detallado
Johnson & Johnson NYSE:JNJ is poised to buy privately held eye disease drug developer Ollin Biosciences for up to $3.4 billion, the Financial Times reported on Sunday, citing people familiar with the matter.Under the terms of the deal being discussed, J&J could pay Ollin’s backers $2.2 billion upfr…
MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.tradingview.com)




